VPC-18005 inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain, and disrupts the ERG binding to DNA. VPC-18005 is a potent inhibitor of luciferase activity^[1].

VPC-18005 is found to inhibit pETS-luc reporter activity in PNT1B-ERG and VCaP cells with IC₅₀ values of 3 and 6 μM, respectively^[1].
VPC-18005 could suppress ERG reporter activity without exhibiting overt cytotoxicity^[1].
VPC-18005 inhibits migration and invasion of ERG-overexpressing cells in vitro^[1].
VPC-18005 can antagonize the metastatic potential of ERG-expressing prostate cells^[1].
The exposure of larvae to 1 or 10 µM of VPC-18005 produced a 20–30% decrease in the dissemination of cancer cells in zebrafsh^[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

319.38

C₁₅H₁₇N₃O₃S

2242480-48-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Miriam S Butler, et al. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer. Oncotarget. 2017 Jun 27;8(26):42438-42454.

  [2]. Haneen Amawi, et al. The use of zebrafish model in prostate cancer therapeutic development and discovery. Cancer Chemother Pharmacol. 2021 Mar;87(3):311-325.